Senores Pharmaceuticals (NSE:SENORES) Change In Receivables: ₹0 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:SENORES Senores Pharmaceuticals Ltd NSE:SENORES
19 GF Score
Price ₹1,428.40
! 7 Warning Signs
View Full Analysis

What is Senores Pharmaceuticals Change In Receivables?

Senores Pharmaceuticals NSE:SENORES -0.14% 19 Change In Receivables is ₹0 Mil as of Jun. 2026. GuruFocus rates NSE:SENORES with a GF Score™ of 19/100. The stock has 7 warning signs investors should review.

Senores Pharmaceuticals's change in receivables for the quarter that ended in Jun. 2026 was ₹0 Mil. It means Senores Pharmaceuticals's Accounts Receivable stayed the same from Mar. 2026 to Jun. 2026 .

Senores Pharmaceuticals's change in receivables for the fiscal year that ended in Mar. 2026 was ₹-1,973 Mil. It means Senores Pharmaceuticals's Accounts Receivable increased by ₹1,973 Mil from Mar. 2025 to Mar. 2026 .

Senores Pharmaceuticals's Accounts Receivable for the quarter that ended in Jun. 2026 was ₹0 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Senores Pharmaceuticals's Days Sales Outstanding for the three months ended in Jun. 2026 was 0.00.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Senores Pharmaceuticals's liquidation value for the three months ended in Jun. 2026 was ₹0 Mil.

Senores Pharmaceuticals  (NSE:SENORES) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Senores Pharmaceuticals's Days Sales Outstanding for the quarter that ended in Jun. 2026 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=0/1802.1*91
=0.00

2. In Ben Graham's calculation of liquidation value, Senores Pharmaceuticals's accounts receivable are only considered to be worth 75% of book value:

Senores Pharmaceuticals's liquidation value for the quarter that ended in Jun. 2026 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=0-0+0.75 * 0+0.5 * 0
=0

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Senores Pharmaceuticals Change In Receivables Related Terms

Senores Pharmaceuticals Change In Receivables Historical Data

* Premium members only.

The historical data trend for Senores Pharmaceuticals's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Senores Pharmaceuticals Change In Receivables Chart

Senores Pharmaceuticals Annual Data
Trend Mar22 Mar23 Mar24 Mar25 Mar26
Change In Receivables
-152.10 -15.36 -571.10 -118.80 -1,973.40

Senores Pharmaceuticals Quarterly Data
Mar22 Mar23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
NSE:SENORES
19GF Score
Senores Pharmaceuticals Ltd NSE:SENORES
Change In Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Senores Pharmaceuticals Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Receivables →
What does a Change In Receivables of ₹0 Mil mean?
Senores Pharmaceuticals (NSE:SENORES) has a Change In Receivables of ₹0 Mil as of Jun. 2026. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Senores Pharmaceuticals and its competitors.
Is Senores Pharmaceuticals' Change In Receivables too high?
Senores Pharmaceuticals' current Change In Receivables is ₹0 Mil. Overall, Senores Pharmaceuticals has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Senores Pharmaceuticals' Change In Receivables compare to LLY and JNJ?
Senores Pharmaceuticals' Change In Receivables of ₹0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Drug Manufacturers company?
A good Change In Receivables depends on the Drug Manufacturers industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Senores Pharmaceuticals and its competitors. Senores Pharmaceuticals's current Change In Receivables is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Senores Pharmaceuticals stock overvalued right now?
Senores Pharmaceuticals (NSE:SENORES) has a current Change In Receivables of ₹0 Mil. The current Change In Receivables is ₹0 Mil. Senores Pharmaceuticals' overall GF Score™ is 19/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For Senores Pharmaceuticals (NSE:SENORES), the current Change In Receivables is ₹0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Senores Pharmaceuticals Business Description

Other Exchanges 544319:India
Address Ambali Bopal Road, 1101 to 1103, 11th floor, South Tower, ONE 42, Opposite Jayantilal Park, Ahmedabad, GJ, IND, 380054
Senores Pharmaceuticals Ltd is a research-driven pharmaceutical company engaged in developing and manufacturing a wide range of pharmaceutical products predominantly for the Regulated Markets of the USA, Canada and United Kingdom across various therapeutic areas and dosage forms, with a presence in Emerging Markets. Its strength lies in identifying, developing and manufacturing a diverse range of specialty, underpenetrated and complex pharmaceutical products establishing the company as a preferred partner to certain customers. Through data analytics, research, market assessment and experienced management, It strategically identifies commercially underpenetrated molecules to launch products in the Regulated and Emerging Markets.
19GF Score

Get the complete analysis for NSE:SENORES

Change In Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,428.40
Price